Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several scientific/trial-design statements are not supported by the provided label excerpts, and multiple indication/demographic claims conflict with the label text (age 3 months+ vs 2 years+). However, some general trial-structure concepts (double-blind, vehicle-controlled, mild to moderate populations, itch/severity endpoints) are broadly consistent with the excerpts.
Category Scores
Accurate Statements
Eucrisa is FDA-approved.
Label excerpts provided include EUCRISA indications and usage; approval status is not explicitly stated in the excerpts, but the presence of labeled sections supports that EUCRISA is an approved FDA-labeled drug.
Trial program enrolled people with mild to moderate atopic dermatitis.
6.1 Clinical Trials Experience: subjects with mild to moderate atopic dermatitis were treated in two vehicle-controlled trials.
Crisaborole vehicle-controlled topical trials were designed so that improvement in the active drug group is statistically separated from improvement in the vehicle group.
14 Clinical Studies: two multicenter, randomized, double-blind, parallel-group, vehicle-controlled trials.
Crisaborole trials used randomized, controlled trial designs.
14 Clinical Studies: randomized, double-blind, vehicle-controlled trials.
Crisaborole trials compared crisaborole against the matching vehicle (base cream).
14 Clinical Studies and 6.1: vehicle-controlled trials; 1012 subjects treated with EUCRISA twice daily vs vehicle.
Unsupported Statements
Eucrisa is a topical treatment for mild to moderate atopic dermatitis (eczema).
Supported by the label excerpts (1 and 2) that EUCRISA is topical treatment of mild to moderate atopic dermatitis, but 'eczema' terminology is not explicitly used in the excerpts; however this is not a direct contradiction—still generally supported. Marked unsupported only if strictly requiring the exact wording; otherwise treated as supported. (If treated as supported, score would improve.)
Clinical development of crisaborole focused on demonstrating symptom improvement.
No explicit description of development focus in the provided label excerpts.
Clinical development emphasized improvement in itch and overall disease severity.
The excerpts mention efficacy endpoints (Day 29 success proportion) but do not describe “overall disease severity” emphasis or “itch” focus in the excerpted endpoint description.
Crisaborole trials used standardized measures of eczema severity and itch response.
The provided excerpt does not describe specific standardized measures for eczema severity/itch.
Eucrisa trials evaluated itch intensity.
The provided excerpt does not explicitly state itch intensity was an evaluated endpoint.
Itch intensity was tracked repeatedly over the first days of treatment in the trials.
No repeated early itch tracking schedule is described in the provided label excerpts.
Eucrisa trials evaluated overall eczema severity using clinician- and patient-reported scoring tools.
No details on clinician- and patient-reported severity scoring tools are provided in the excerpts.
Eucrisa trials evaluated treatment success rates based on achieving predefined symptom thresholds.
The excerpted label text indicates a primary endpoint is “proportion of subjects at Day 29 who achieved success,” but does not provide the definition (predefined thresholds).
Itch and visible/inflammatory eczema severity are the main day-to-day problems patients and clinicians treat in atopic dermatitis.
Not described in the provided prescribing information excerpts.
Crisaborole trial design aimed to look for early itch relief after starting treatment.
The excerpt does not state an early itch-relief objective.
Crisaborole trial design assessed whether symptom improvements persisted through the treatment period used in each study.
The excerpt notes application for 28 days and includes results tables, but does not state persistence assessment intent/objective.
Eucrisa clinical trials included pediatric and adult populations.
14 Clinical Studies excerpt mentions subjects age 2 to 79 years and a pediatric trial (Trial 3: 3 months to <18 years), but does not explicitly say pediatric and adult included across the “clinical trials” broadly; partially implied. Treated as unsupported due to lack of explicit “included” wording across trials.
The trial program populations were consistent with the eventual labeled indication covering children aged 2 years and older.
Label pediatric age range is 3 months and older (per Indications and Usage excerpt); this statement is inconsistent (also contradiction via age mismatch).
Patients treated with Eucrisa had better improvement in itch than those using vehicle.
The excerpt provided does not explicitly report itch-specific comparative results.
Patients treated with Eucrisa had better improvement in eczema severity than those using vehicle.
The excerpt does not provide the specific comparative eczema severity results in the provided text.
Contradictions
High
AI Statement
Eucrisa is indicated for patients aged 2 years and older.
Label Reference
1 INDICATIONS AND USAGE: “mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.”
Important Omissions
Age of indication should be 3 months of age and older (not 2 years and older).
Importance:
High
If discussing dosing: EUCRISA is applied as a thin layer twice daily; once clinical effect is achieved consider reducing to once daily (and it is for topical use only; not ophthalmic, oral, or intravaginal).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The statement that the indication is for ages 2 years and older directly conflicts with the label pediatric indication (3 months and older), which could lead to under-use or incorrect labeling. Other claims are largely unsupported rather than directly unsafe, since they do not describe contraindications, warnings, or dosing instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Pediatric indication age is incorrect (2 years+ vs labeled 3 months+). Multiple endpoint/itch/severity measurement and comparative effectiveness statements are not supported by the provided label excerpts.
Suggested Improvement
Replace the age requirement with “3 months of age and older” and remove or qualify trial endpoint details (itch intensity tracking, severity scoring tools, early itch relief objective, and comparative itch/severity results) unless explicitly stated in the provided FDA label excerpts.